Mechanism of long non-coding RNA in prostate cancer

Abstract

Zhang Xiaofei, Hu Jianpeng, Cui Feilun. Mechanism of long non-coding RNA in prostate cancer[J]. Journal of International Oncology, 2021, 48(2): 117-120.

References36

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020,70(1):7-30. DOI: 10.3322/caac.21590. doi:10.3322/caac.21590pmid:31912902
[2]	Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers[J]. Cells, 2019,8(9):1015. DOI: 10.3390/cells8091015. doi:10.3390/cells8091015
[3]	Cui Z, Ren S, Lu J, et al. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor[J]. Urol Oncol, 2013,31(7):1117-1123. DOI: 10.1016/j.urolonc.2011.11.030. doi:10.1016/j.urolonc.2011.11.030pmid:22264502
[4]	Yang Q, Cui ZL, Wang Q, et al. PlncRNA-1 induces apoptosis through the Her-2 pathway in prostate cancer cells[J]. Asian J Androl, 2017,19(4):453-457. DOI: 10.4103/1008-682X.178849. doi:10.4103/1008-682X.178849pmid:27232851
[5]	Ghafouri-Fard S, Esmaeili M, Taheri M. H19 lncRNA: roles in tumorigenesis[J]. Biomed Pharmacother, 2020,123:109774. DOI: 10.1016/j.biopha.2019.109774. doi:10.1016/j.biopha.2019.109774pmid:31855739
[6]	Zhu M, Chen Q, Liu X, et al. lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI[J]. FEBS J, 2014,281(16):3766-3775. DOI: 10.1111/febs.12902. doi:10.1111/febs.12902
[7]	Singh N, Padi SKR, Bearss JJ, et al. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth[J]. Mol Oncol, 2020,14(5):974-990. DOI: 10.1002/1878-0261.12662. doi:10.1002/1878-0261.12662pmid:32146726
[8]	Ren S, Liu Y, Xu W, et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer[J]. J Urol, 2013,190(6):2278-2287. DOI: 10.1016/j.juro.2013.07.001. doi:10.1016/j.juro.2013.07.001pmid:23845456
[9]	Wang D, Ding L, Wang L, et al. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer[J]. Oncotarget, 2015,6(38):41045-41055. DOI: 10.18632/oncotarget.5728. doi:10.18632/oncotarget.5728pmid:26516927
[10]	Wang F, Ren S, Chen R, et al. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer[J]. Oncotarget, 2014,5(22):11091-11102. DOI: 10.18632/oncotarget.2691.
[11]	Jin SJ, Jin MZ, Xia BR, et al. Long non-coding RNA DANCR as an emerging therapeutic target in human cancers[J]. Front Oncol, 2019,9:1225. DOI: 10.3389/fonc.2019.01225. doi:10.3389/fonc.2019.01225pmid:31799189
[12]	Zhao HF, Zhang ZC, Shi BK, et al. DANCR sponges miR-135a to regulate paclitaxel sensitivity in prostate cancer[J]. Eur Rev Med Pharmacol Sci, 2019,23(16):6849-6857. DOI: 10.26355/eurrev_201908_18724. doi:10.26355/eurrev_201908_18724pmid:31486484
[13]	Ma Y, Fan B, Ren Z, et al. Long noncoding RNA DANCR contri-butes to docetaxel resistance in prostate cancer through targeting the miR-34a-5p/JAG1 pathway[J]. Onco Targets Ther, 2019,12:5485-5497. DOI: 10.2147/OTT.S197009. doi:10.2147/OTT.S197009pmid:31371987
[14]	Ji J, Dai X, Yeung SJ, et al. The role of long non-coding RNA GAS5 in cancers[J]. Cancer Manag Res, 2019,11:2729-2737. DOI: 10.2147/CMAR.S189052. doi:10.2147/CMAR.S189052pmid:31114330
[15]	Xie X, Dai J, Huang X, et al. MicroRNA-145 inhibits proliferation and induces apoptosis in human prostate carcinoma by upregulating long non-coding RNA GAS5[J]. Oncol Lett, 2019,18(2):1043-1048. DOI: 10.3892/ol.2019.10419. doi:10.3892/ol.2019.10419pmid:31423164
[16]	Yang J, Hao T, Sun J, et al. Long noncoding RNA GAS5 modulates α-Solanine-induced radiosensitivity by negatively regulating miR-18a in human prostate cancer cells[J]. Biomed Pharmacother, 2019,112:108656. DOI: 10.1016/j.biopha.2019.108656. doi:10.1016/j.biopha.2019.108656pmid:30970507
[17]	Guo C, Qi Y, Qu J, et al. Pathophysiological functions of the lncRNA TUG1[J]. Curr Pharm Des, 2020,26(6):688-700. DOI: 10.2174/1381612826666191227154009. doi:10.2174/1381612826666191227154009pmid:31880241
[18]	Xu T, Liu CL, Li T, et al. LncRNA TUG1 aggravates the progre-ssion of prostate cancer and predicts the poor prognosis[J]. Eur Rev Med Pharmacol Sci, 2019,23(11):4698-4705. DOI: 10.26355/eurrev_201906_18062. doi:10.26355/eurrev_201906_18062pmid:31210308
[19]	Yang G, Yin H, Lin F, et al. Long noncoding RNA TUG1 regulates prostate cancer cell proliferation, invasion and migration via the Nrf2 signaling axis[J]. Pathol Res Pract, 2020,216(4):152851. DOI: 10.1016/j.prp.2020.152851. doi:10.1016/j.prp.2020.152851pmid:32057513
[20]	Pu J, Wei H, Tan C, et al. Long noncoding RNA SNHG14 facilitates hepatocellular carcinoma progression through regulating miR-4673/SOCS1[J]. Am J Transl Res, 2019,11(9):5897-5904. pmid:31632558
[21]	Li L, Zhang R, Li SJ. Long noncoding RNA SNHG14 promotes ovarian cancer cell proliferation and metastasis via sponging miR-219a-5p[J]. Eur Rev Med Pharmacol Sci, 2019,23(10):4136-4142. DOI: 10.26355/eurrev_201905_17915. doi:10.26355/eurrev_201905_17915pmid:31173283
[22]	Ye T, Zhang N, Wu W, et al. SNHG14 promotes the tumorigenesis and metastasis of colorectal cancer through miR-32-5p/SKIL axis[J]. In Vitro Cell Dev Biol Anim, 2019,55(10):812-820. DOI: 10.1007/s11626-019-00398-5. doi:10.1007/s11626-019-00398-5pmid:31471872
[23]	Xu ZN, Wang ZX, Xu L, et al. Long noncoding RNA SNHG14 exerts oncogenic functions in lung adenocarcinoma through acting as a sponge to miR-613[J]. Eur Rev Med Pharmacol Sci, 2019,23(24):10810-10817. DOI: 10.26355/eurrev_201912_19784. doi:10.26355/eurrev_201912_19784pmid:31858549
[24]	Liu Z, Yan Y, Cao S, et al. Long non-coding RNA SNHG14 contributes to gastric cancer development through targeting miR-145/SOX9 axis[J]. J Cell Biochem, 2018,119(8):6905-6913. DOI: 10.1002/jcb.26889. doi:10.1002/jcb.26889pmid:29667771
[25]	Ji N, Wang Y, Bao G, et al. LncRNA SNHG14 promotes the progression of cervical cancer by regulating miR-206/YWHAZ[J]. Pathol Res Pract, 2019,215(4):668-675. DOI: 10.1016/j.prp.2018.12.026. doi:10.1016/j.prp.2018.12.026pmid:30611620
[26]	Sun B, Ke KB, Liu DF, et al. Long noncoding RNA SNHG14 acts as an oncogene in prostate cancer via targeting miR-613[J]. Eur Rev Med Pharmacol Sci, 2020,24(2):633-638. DOI: 10.26355/eurrev_202001_20039. doi:10.26355/eurrev_202001_20039pmid:32016964
[27]	Ghafouri-Fard S, Taheri M. Maternally expressed gene 3 (MEG3): a tumor suppressor long noncoding RNA[J]. Biomed Pharmacother, 2019,118:109129. DOI: 10.1016/j.biopha.2019.109129. doi:10.1016/j.biopha.2019.109129pmid:31326791
[28]	Li J, Zi Y, Wang W, et al. Long noncoding RNA MEG3 inhibits cell proliferation and metastasis in chronic myeloid leukemia via targeting miR-184[J]. Oncol Res, 2018,26(2):297-305. DOI: 10.3727/096504017X14980882803151. doi:10.3727/096504017X14980882803151pmid:28653609
[29]	Wu M, Huang Y, Chen T, et al. LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis[J]. J Cell Mol Med, 2019,23(1):29-38. DOI: 10.1111/jcmm.13658. doi:10.1111/jcmm.13658pmid:30565858
[30]	Luo G, Wang M, Wu X, et al. Long non-coding RNA MEG3 inhi-bits cell proliferation and induces apoptosis in prostate cancer[J]. Cell Physiol Biochem, 2015,37(6):2209-2220. DOI: 10.1159/000438577. doi:10.1159/000438577pmid:26610246
[31]	Zhang WY, Liu YJ, He Y, et al. Down-regulation of long non-coding RNA ANRIL inhibits the proliferation, migration and invasion of cervical cancer cells[J]. Cancer Biomark, 2018,23(2):243-253. DOI: 10.3233/CBM-181467. doi:10.3233/CBM-181467pmid:30198868
[32]	Zhang JJ, Wang DD, Du CX, et al. Long noncoding RNA ANRIL promotes cervical cancer development by acting as a sponge of miR-186[J]. Oncol Res, 2018,26(3):345-352. DOI: 10.3727/096504017X14953948675449. doi:10.3727/096504017X14953948675449pmid:28550682
[33]	Yu G, Liu G, Yuan D, et al. Long non-coding RNA ANRIL is associated with a poor prognosis of osteosarcoma and promotes tumorige-nesis via PI3K/Akt pathway[J]. J Bone Oncol, 2018,11:51-55. DOI: 10.1016/j.jbo.2018.02.002. doi:10.1016/j.jbo.2018.02.002pmid:29520337
[34]	Deng W, Zhang Y, Cai J, et al. LncRNA-ANRIL promotes gastric cancer progression by enhancing NF-κB signaling[J]. Exp Biol Med (Maywood), 2019,244(12):953-959. DOI: 10.1177/1535370219860207. doi:10.1177/1535370219860207
[35]	Ma J, Li T, Han X, et al. Knockdown of lncRNA ANRIL suppre-sses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2018,144(2):205-214. DOI: 10.1007/s00432-017-2543-y. doi:10.1007/s00432-017-2543-ypmid:29127494
[36]	Zhao B, Lu YL, Yang Y, et al. Overexpression of lncRNA ANRIL promoted the proliferation and migration of prostate cancer cells via regulating let-7a/TGF-β1/ Smad signaling pathway[J]. Cancer Biomark, 2018,21(3):613-620. DOI: 10.3233/CBM-170683. doi:10.3233/CBM-170683pmid:29278879

Mechanism of long non-coding RNA in prostate cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References36

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Zhao Xin, Fan Xuewu, Tian Long, Hu Yimin.Application and evaluation study of 3D ultrasound in image guided radiotherapy for prostate cancer[J]. Journal of International Oncology, 2024, 51(1): 43-49.
[2]	Du Xiao, Zhou Juying.Stereotactic body radiotherapy for localized prostate cancer[J]. Journal of International Oncology, 2021, 48(5): 313-316.
[3]	Ji Chundong, Liu Kai, Feng Yue, Wang Fei, Yang Jun, Xue Rongbo.Predictive value of PSAMR combined with PI-RADS v2 score in high-grade prostate cancer[J]. Journal of International Oncology, 2020, 47(12): 723-727.
[4]	Zhang Jiawei, Wu Jianchen.Application of exosomes in prostates cancer[J]. Journal of International Oncology, 2020, 47(10): 634-636.
[5]	XU Yao-Zong, GU Xiao, WANG Fei, DING Xue-Fei.Molecular mechanisms of castrationresistant prostate cancer progressed from prostate cancer by androgen deprivation treatment[J]. Journal of International Oncology, 2018, 45(8): 506-509.
[6]	Huang Geng, Jiang Weidong, Mao Qing, Gui Dingwen.Effect of microRNA206 on the growth of prostate cancer cells by interfering with the expression of CDK4 and GAK[J]. Journal of International Oncology, 2017, 44(7): 485-489.
[7]	Zhou Qidong, Jiang Guangliang, Xu Ke.Research progress of glucocorticoid receptor in urological malignant tumors[J]. Journal of International Oncology, 2017, 44(6): 476-.
[8]	FAN Lu-Lu, LIAO Cheng-Gong, HUANG Jian-Guo, YIN Hang, QIAN Men-Long, WAN Nao, LU Ning.Prognostic value of prechemotherapy serum cystatin C in patients with castrationresistant prostate cancer[J]. Journal of International Oncology, 2017, 44(5): 356-360.
[9]	Shen Junlong, Liu Quanhai, Liu Li, Nan Shuliang, Cheng Yongyi, Zhou Jiancheng..Application of improved 13-core prostate biopsy in the diagnosis of prostate cancer[J]. Journal of International Oncology, 2017, 44(12): 907-910.
[10]	Liu Weishuai, Zeng Yaqi, Shao Yuejuan, Wang Kun.Dietary fiber intake and risk of prostate cancer: a Metaanalysis[J]. Journal of International Oncology, 2016, 43(10): 758-764.
[11]	Ma Qiang, Zheng Junfang, Jiao Yanna, Gao Honglin, Li Deguan, Liu Jianfeng, Liu Qiang, Song Naling.RNA interference gene therapy targeting NHERF1 inhibits proliferation of prostate cancer cell line PC-3M[J]. Journal of International Oncology, 2015, 42(1): 14-17.
[12]	ZHANG Zhen-Yu, ZHANG Yu-Feng, ZHANG Hong-Wei.Expression and clinical significance of transcription factor Sox2 in human prostate cancer[J]. Journal of International Oncology, 2014, 41(11): 875-878.
[13]	Wang Ying, Li Xuyuan, Lin Yingcheng.Advance of treatment in hormone refractory prostate cancer[J]. Journal of International Oncology, 2014, 41(1): 56-59.
[14]	HU Ping, SI Tong-Guo, GUO Zhi.Therapeutic progress of locally advanced prostate cancer[J]. Journal of International Oncology, 2013, 40(3): 225-227.
[15]	WANG Yan, WANG Feng-Ling, MOU Yan-Ling, LI Jun.Effects of oldhamianoside Ⅱ on the invasive ability of prostatic carcinoma cells[J]. Journal of International Oncology, 2012, 39(7): 551-554.